· 31/03/2016
Proxima A: Epidemiological study of the progression of Geographic Atrophy secondary to Age-Related Macular Degeneration (GX29633)
· 31/03/2016
Proxima B: Epidemiological study of the progression of Geographic Atrophy secondary to Age-Related Macular Degeneration (GX29639)
· 21/09/2015
HARRIER: Clinical trial on patients with choroidal neovascularisation secondary to AMD
· 29/01/2015
CHROMA: Clinical Trial of Lampalizumab for Geographic Atrophy Secondary to Age-Related Macular Degeneration
· 19/12/2014
FOVISTA NR: Clinical Trial for neovascular age-related macular degeneration
· 21/12/2014
LITE: Development of Advanced Laser Imaging Techniques for the anterior and posterior Eye
· 01/01/2015
FOVISTA: Clinical Trial for subfoveal neovascular age-related macular degeneration
· 19/03/2014
Clinical trial in antiretroviral-naive patients with choroidal neovascularization secondary to AMD
· 31/03/2014
Phase III Study of Lampalizumab in patients with geographic atrophy secondary to AMD
· 20/12/2014
MPL4 GA: A phase I study in subjects with geographic atrophy secondary to dry age-related macular degeneration
· 20/12/2014
Oral Omega 3 GA. A phase II in subjects with geographic atrophy secondary to AMD
· 02/07/2014
Prospective, randomised, placebo-controlled, double-masked, three-armed, multicenter Phase II/III trial to establish the safety and efficacy of a topical treatment of Neovascular Glaucoma
· 02/07/2014
JETREA M-13-056 Assessment of anatomical and functional outcomes in patients treated with ocriplasmin for vitreomacular traction/symptomatic vitreomacular adhesion
· 19/03/2014
TREND: A phase IIIb, randomized, a 12-month, Visual Acuity assessor-masked, interventional study assessing the efficacy and safety of the Treat and Extend vs monthly regimens of 0.5 mg ranibizumab in patients with newly diagnosed nAMD
· 19/03/2014
MACBETH. Phase IV Study to evaluate the efficacy of aflibercept in subjects with neovascular Age-related Macular Degeneration (wAMD), without optimal response to repeated monthly intravitreal injections of Anti Vascular Endothelial Growth Factor (Anti VEGF-A) Therapy